Physician profile
Roderick David Ekmark
NPI 1063693398
$1,051.28
in general payments reported to CMS, 2019-2025
15 companies · $263 in 2025
The $263 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.32 · 2021: $155 · 2022: $27.06 · 2023: $49.09 · 2024: $461 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $229.79 | 2022-2024 | |
| Astrazeneca Pharmaceuticals LP | $162.55 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $133.51 | 2021-2025 | Otezla, Repatha, Otezla |
| Lilly USA, LLC | $126.05 | 2019-2025 | Mounjaro |
| Novo Nordisk INC | $110.56 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $63.92 | 2024-2025 | Dexcom G6 Transmitter |
| Pfizer INC. | $54.76 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.22 | 2021-2024 | Trintellix |
| Exact Sciences Corporation | $35.93 | 2024-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $26.33 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.77 | 2019 | |
| Glaxosmithkline, LLC. | $14.17 | 2024 | Trelegy Ellipta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.98 | 2019 | |
| Nevro Corp. | $10.90 | 2019 | |
| Phathom Pharmaceuticals, INC. | $10.84 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roderick Ekmark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.